NVSTHIGH SIGNALFINANCIAL10-K

NVST achieved a dramatic turnaround from a $1.0B operating loss to $216.1M operating profit, signaling a major business transformation.

This represents one of the most significant corporate turnarounds in recent filings, with the company moving from substantial losses to profitability across all key metrics. The 120.8% swing in operating income and 104.2% improvement in net income suggests either a major restructuring has paid off, asset impairments from the prior year have been resolved, or fundamental business improvements have taken hold.

Comparing 2026-02-12 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

NVST delivered an exceptional financial turnaround, moving from deep losses to solid profitability with operating income swinging +120.8% and net income improving +104.2%. While the company increased investments with R&D up 15% and capex up 34%, and saw working capital growth with inventory (+19.5%) and receivables (+18.3%) increases, operating cash flow declined 18.1% despite the profit improvement. The overall picture signals a company that has successfully navigated through a major restructuring or impairment cycle and is now reinvesting for growth, though investors should monitor whether the cash flow/earnings divergence reflects timing differences or underlying business quality issues.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+120.8%
-$1.0B$216.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+104.2%
-$1.1B$47.0M

Net income grew 104.2% — bottom-line growth signals improving overall business health.

Interest Expense
P&L
+65.1%
$38.4M$63.4M

Interest expense surged 65.1% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
+34%
$33.8M$45.3M

Capital expenditure jumped 34% — major investment cycle underway; assess returns on deployment.

Inventory
Balance Sheet
+19.5%
$241.0M$288.1M

Inventory built 19.5% — monitor whether demand supports this build or if write-downs may follow.

Accounts Receivable
Balance Sheet
+18.3%
$363.0M$429.6M

Receivables grew 18.3% — monitor days sales outstanding for collection efficiency.

Operating Cash Flow
Cash Flow
-18.1%
$336.5M$275.7M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

R&D Expense
P&L
+15%
$99.1M$114.0M

R&D investment increased 15% — signals commitment to future product development, though near-term margin impact.

Cash & Equivalents
Balance Sheet
+13.3%
$1.1B$1.2B

Cash grew 13.3% — improving liquidity position supports investment and shareholder returns.

Current Assets
Balance Sheet
+13.3%
$1.8B$2.0B

Current assets grew 13.3% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-13
ADDED
The aggregate market value of the common stock of the Registrant held by non-affiliates on June 27, 2025, the last business day of the Registrant s most recently completed second fiscal quarter, was $ 2.5 billion (based upon the closing price of $19.67 of the Registrant's common stock as reported on the New York Stock Exchange on such date).
BUSINESS Overview Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives.
We help our customers deliver the best possible patient care through industry-leading products, solutions, and technology.
Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the human smile.
We were formed in 2018 as a wholly-owned subsidiary of Danaher Corporation.
+7 more — sign up free →
REMOVED
The aggregate market value of the common stock of the Registrant held by non-affiliates on June 28, 2024, the last business day of the Registrant s most recently completed second fiscal quarter, was $ 2.2 billion (based upon the closing price of $16.63 of the Registrant's common stock as reported on the New York Stock Exchange on such date).
BUSINESS Overview Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives by digitizing, personalizing and democratizing oral care.
We help our customers deliver the best possible patient care through industry-leading dental consumables, solutions, technologies, and services.
Our diversified portfolio of solutions covers a broad range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile.
We offer comprehensive solutions to support implant-based tooth replacements, orthodontic treatments, and diagnostic solutions.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →